AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06072677 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Minds Program
Description: The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
Study NCT05389657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based training
Description: Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.
Study NCT05389657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live training
Description: The live training will be delivered by two trainers over the course of two days via Zoom.
Study NCT05866562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;
Study NCT05866562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
Study NCT04888429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Patients received camrelizumab 200 mg every 3 weeks
Study NCT04888429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Patients received Famitinib 20 mg once per day
Study NCT04873453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
Study NCT04873453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.
Study NCT04873453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study NCT04921527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiauranib
Description: 50mg orally once daily
Study NCT04921527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg orally once daily
Study NCT06081751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pretest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I
Study NCT04921527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
Study NCT04921527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
Study NCT06457360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Application of sterile gauze after extraction for hemostasis
Study NCT06457360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper
Description: Application of sterile gauze after extraction for hemostasis
Study NCT06457360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: Application of sterile gauze after extraction for hemostasis
Study NCT06648304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01 tablets
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Study NCT06648304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Study NCT06649526 — intervention group
Intervention type: OTHER
Intervention: endotracheal intubation with videolaryngoscope
Description: The present study will compare the images of two different VLs with Macintosh blades (the McGrath videolaryngoscope and the Hugemed videolaryngoscope) in both indirect (screen images) and direct (images viewed through the mouth) laryngoscopy.
Study NCT06648616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBT
Description: Elastic Band Resistance Training
Study NCT06081751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pretest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I
Study NCT06081751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Posttest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I
Study NCT06081751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posttest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I
Study NCT05690789 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT05681624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Maternal oxygen supplementation
Description: Maternal oxygen supplementation 10 liters/minute via nonrebreather mask
Study NCT05681624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Room air
Description: Room air, no mask
Study NCT05836974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex-utero cord blood collection
Description: SCU units are collected after placental delivery (ex-utero) by trained obstetric personnel. The cord is clamped at one minute postpartum. Once the placenta is expelled, it is rapidly transported to the collection area, which contains supplies and a surgical table designed for ex-utero SCU collection. This table has a top tray supported by an armrest. The placenta is placed on this specially designed tray with a central hole that allows the umbilical cord to hang. Proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol. Subsequently, the umbilical vein is cannulated at the most distal point of the placenta, and placental blood is collected by gravity into a sterile bag. Gentle massage can be applied to the placenta to continue draining blood by gravity. If visible blood remains, a second puncture can be made by bringing the needle insertion point closer to the placenta.
Study NCT05836974 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-utero cord blood collection
Description: The cord blood is clamped in a delayed modality, defined as after at least 1 minute after delivery. The cord is sterilized, and cord blood is collected using aseptic technique (proper asepsis of the cord is first performed with povidone-iodine and then with 70% alcohol). Blood is allowed to flow by gravity and the needle is removed when blood flow ceases.
Study NCT06350695 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low grade compression stockings (10-15 mmHg)
Description: Patient will wear low grade compression stockings (10-15 mmHg) at least 8 hours a day 5 days a week
Study NCT06350695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high grade compression stockings (20-30 mmHg)
Description: Patient will wear low grade compression stockings (20-30 mmHg) at least 8 hours a day 5 days a week
Study NCT05047731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Description: Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded
Study NCT06328400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Study NCT06328400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension Placebo
Description: Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, twice a day Experimental: Deuremidevir Hydrobromide for Suspension 900mg group, 3 times a day Experimental: Deuremidevir Hydrobromide for Suspension 1200mg group, twice a day
Study NCT05740683 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-QuiC
Description: RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.
Study NCT05644821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex intervention
Description: The intervention has several elements:~1. Regular symptom monitoring via ePROMs~2. Alarm when defined thresholds of EPIC-26 or PHQ-4 are reached or exceeded, 3.) In case of alarm, standardized telephone contact by a study nurse at the treating center with the offer to coordinate a urological consultation at the center, 4.) if requested by the patient: a urological consultation at the treating prostate cancer center by urologists trained in the PRO-P study,~4) content of the consultation: if necessary, the guideline-compliant initiation of further diagnostics and therapy including in this context necessary follow-up contacts and 5) postal communication of the ePROM results in case of an alarm as well as postal dispatch of a report of the findings in case of a urological consultation at the treating prostate cancer center to the practicing, treating urologist.
Study NCT05644821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: current clinical practice
Description: current clinical practice
Study NCT06268405 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: Detects cell-free DNA (cfDNA) circulating in the blood by whole-genome sequencing (WGS). It also detects cfDNA containing epigenetic marks by cell-free methylated DNA immunoprecipitation and high throughput sequencing assays and may determine the concordance of genomic alterations between tumour tissue (if available) and matched plasma samples by WGS.
Study NCT06268405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography (PEM)
Description: PEM produces high-sensitivity images of breasts with low levels of F-18 FDG.
Study NCT05960448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation (TSCS)
Description: This is electrical stimulation delivered to the spinal cord through the skin and tissue using a cathode electrode to deliver the stimulation and anode electrodes to ground the circuit.
Study NCT05960448 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Spinal Cord Stimulation
Description: This is designed to appear like transcutaneous spinal cord stimulation without actually delivering the stimulation.
Study NCT06648369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAX-ICH care bundle
Description: The MAX-ICH care bundle is a comprehensive treatment approach for intracerebral hemorrhage (ICH). Patients receive 72 hours of care in a high-dependency unit like an ICU or hyperacute stroke unit. Intensive blood pressure control is used if systolic blood pressure exceeds 140mmHg, with rapid reduction to below 140mmHg within 60 minutes, and maintenance at or above 110mmHg for at least 75% of the time, with variability kept under 20%. The protocol includes rapid reversal of anticoagulation within 60 minutes, administration of tranexamic acid (1g bolus within 60 minutes, followed by 1g over 8 hours), and neurosurgical evaluation within 60 minutes. Additionally, family counseling is provided to avoid Do-Not-Resuscitate orders during the first 72 hours.
Study NCT06648369 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: The control group will be treated according to the hospital's standard protocol for patients with spontaneous intracerebral hemorrhage, based on the guidelines of the European Stroke Organisation (ESO). The ESO develops evidence-based recommendations for the optimal care of stroke patients. The recommended immediate measures include: immediate stabilization and assessment, blood pressure control and reduction, brain imaging, surgical intervention for large hemorrhages, coagulation control, and monitoring of intracranial pressure. The specific application of these measures varies depending on the hospital and the treating physicians.
Study NCT06647680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles
Description: Receive the experimental combination of drugs (chemoradiation (Oxaliplatin and Capecitabine) + PD-1 inhibitor (Tislelizumab) for 3 cycles prior to surgery and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years. The time in the study will take approximately four - six hours during pre-study, study and end of study visits.
Study NCT05699356 — intervention group
Intervention type: OTHER
Intervention: Non Surgical treatment
Description: Non Surgical
Study NCT06649539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: 4 Series given to each participant, 6 weeks apart. Medication administered on back-to-back days. If failing to achieve an adequate response, men may receive up to 2 additional series 9-12 months after the 4th series.~Total of 0.9 mg administered with each series, diluted to 0.8 mL
Study NCT06649539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RestoreX
Description: Restorex initiated beginning on post-injection day 3 or as soon as tolerated - 30 min daily, continuing until 6 weeks after final injection of the final CCH series.
Study NCT06649539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Men will be prescribed sildenafil 25 mg nightly beginning treatment day 2 until 6 weeks after final injection of the final series.
Study NCT06648057 — intervention group
Intervention type: DRUG
Intervention: lenvatinib plus pembrolizumab
Description: * The collection of peripheral blood samples will follow the schedule below (20 cc per collection, up to 5 times):~* Before systemic therapy, at 3 weeks after starting systemic therapy (Cycle 1), at 6 weeks (Cycle 2)~* (If possible) at the time of confirmed partial response (1 time), and at the time of disease progression (1 time).~* Additional tumor tissue samples will be collected only if possible, according to the following schedule:~If the patient undergoes surgery or additional biopsy related to treatment (collected from preserved specimens).
Study NCT06649396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dried Blood Spot
Description: Comparing analysis results between dried blood spot and plasma
Study NCT06649396 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Analysis on plasma
Description: Analysis on plasma
Study NCT06105970 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: cross sectional study#no intervention
Study NCT03673748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSC)
Description: Endovenous injection of MSV in saline solution
Study NCT03673748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Endovenous injection of saline solution without cells
Study NCT05699356 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic drilling
Description: Surgical intervension
Study NCT05699356 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treatment of Poly cystic ovary for infertility by Life style modification
Description: Non Surgical
Study NCT05699356 — intervention group
Intervention type: PROCEDURE
Intervention: Treatment of Poly cystic ovary for infertility by Assisted reproductive technique
Description: Surgical intervention
Study NCT04956419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8008 capsule
Description: once daily for 2 days(Day 1 and Day 2),oral
Study NCT04956419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole capsule
Description: once daily for 2 days(Every 72 hours) ,oral
Study NCT05977257 — intervention group
Intervention type: DEVICE
Intervention: VitaFlow® Transcatheter Aortic Valve Replacement System
Description: This study is an observational study, for who have joined the VitaFlow® Catheter Aortic Valve System pre-market trial
Study NCT06309095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of VDW Silver Endodontic motor
Description: All patients will be subjected to local anesthesia with articaine hydrochloride (Maxicaine, Istanbul) containing 1:100,000 adrenaline. After the entrance cavities of the teeth are opened, a rubber dam will be applied to the relevant teeth for isolation from the oral environment. After the entrance cavity is opened, the working length of the canals will be determined with the help of a No. 10 K-file (Dentsply Maillefer, Ballaigues, Switzerland) canal file and an electronic apex finder (Woodpex III, Woodpecker Medical Instrument Co, Guilin, China). In both groups, it was planned to use the NiTi rotary instrument system using V Taper Gold (Fanta Dental Material, Shanghai, China) files with the help of VDW.Silver endomotor (VDW, München, Germany). The endodontic motor will be used to adjust different speed and torque values during root canal treatment. Post-operative pain caused by different speed and torque values will be compared.
Study NCT06241196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant
Description: Implant will be placed through the surgical guide in the extraction socket
Study NCT06241196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant
Description: Implant will be placed through the surgical guide in the extraction socket
Study NCT06241196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Socket Therapy
Description: tunnel incision will be made in labial vestibule
Study NCT05329584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSpace Subacromial Tissue Spacer
Description: Rotator Cuff Tear Treatment
Study NCT05977127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comirnaty
Description: Administration of Comirnaty vaccine